Drug:
Reaction: NO ADVERSE EVENT
20250101 - 20251231
No. 901 - 1000
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 901 | 25069741 |
US |
2 | |
No adverse event, Product use issue, Product physical issue, |
||||
LISDEXAMFETAMINE DIMESYLATE, |
||||
| 902 | 25069849 |
US |
8 | 2 |
Product storage error, No adverse event, |
||||
| 903 | 25070008 |
US |
||
Recalled product administered, No adverse event, |
||||
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, |
||||
| 904 | 25070103 |
US |
||
Device malfunction, No adverse event, |
||||
PEGFILGRASTIM-CBQV, |
||||
| 905 | 25070946 |
GB |
63 | 2 |
No adverse event, |
||||
DENOSUMAB, FULVESTRANT, RIBOCICLIB, RIBOCICLIB, |
||||
| 906 | 25071376 |
US |
60 | 2 |
Off label use, No adverse event, |
||||
DATOPOTAMAB DERUXTECAN, |
||||
| 907 | 25061256 |
US |
59 | 2 |
No adverse event, Off label use, |
||||
RITUXIMAB, |
||||
| 908 | 25061476 |
US |
||
Device delivery system issue, No adverse event, Wrong technique in product usage process, |
||||
TOCILIZUMAB, |
||||
| 909 | 25061496 |
US |
||
No adverse event, Product preparation issue, |
||||
VEDOLIZUMAB, |
||||
| 910 | 25061669 |
US |
46 | 2 |
Off label use, No adverse event, |
||||
OMALIZUMAB, |
||||
| 911 | 25061811 |
US |
17 | 1 |
Off label use, No adverse event, |
||||
OCRELIZUMAB, |
||||
| 912 | 25061836 |
GB |
63 | |
No adverse event, |
||||
FULVESTRANT, FULVESTRANT, RIBOCICLIB, DENOSUMAB, |
||||
| 913 | 25062061 |
JP |
68 | 1 |
No adverse event, |
||||
FOSTAMATINIB, FOSTAMATINIB, FOSTAMATINIB, FOSTAMATINIB, FOSTAMATINIB, ELTROMBOPAG OLAMINE, ELTROMBOPAG OLAMINE, ELTROMBOPAG OLAMINE, |
||||
| 914 | 25062124 |
US |
2 | |
No adverse event, |
||||
LURBINECTEDIN, |
||||
| 915 | 25062255 |
US |
53 | 1 |
Off label use, No adverse event, |
||||
VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR, VALGANCICLOVIR HYDROCHLORIDE POWDER,, GANCICLOVIR SODIUM, GANCICLOVIR, PANTOPRAZOLE, EPINEPHRINE, ADRENALINUM, |
||||
| 916 | 25062497 |
US |
53 | 2 |
Off label use, No adverse event, |
||||
TOCILIZUMAB, TOCILIZUMAB, |
||||
| 917 | 25062504 |
US |
15 | 2 |
Device defective, Product complaint, Product dose omission issue, No adverse event, |
||||
SOMATROPIN, |
||||
| 918 | 25062669 |
US |
||
Recalled product administered, No adverse event, |
||||
RAMIPRIL, |
||||
| 919 | 25062705 |
US |
||
Intercepted product storage error, No adverse event, |
||||
RITUXIMAB, TOCILIZUMAB, |
||||
| 920 | 25062820 |
US |
||
Product prescribing error, No adverse event, |
||||
OMALIZUMAB, |
||||
| 921 | 25062824 |
US |
2 | |
Drug ineffective, No adverse event, |
||||
OMALIZUMAB, OMALIZUMAB, |
||||
| 922 | 25062868 |
US |
||
Wrong technique in product usage process, No adverse event, |
||||
AMLODIPINE BESYLATE, |
||||
| 923 | 25063028 |
US |
39 | |
Drug dose omission by device, Device delivery system issue, No adverse event, |
||||
ALBUTEROL SULFATE, MONTELUKAST SODIUM, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, SERTRALINE HYDROCHLORIDE, |
||||
| 924 | 25063114 |
US |
34 | |
Wrong technique in product usage process, No adverse event, Incorrect dose administered, |
||||
ALBUTEROL SULFATE, |
||||
| 925 | 25063174 |
US |
1 | |
No adverse event, Product availability issue, |
||||
VEDOLIZUMAB, |
||||
| 926 | 25063297 |
US |
32 | |
Drug dose omission by device, Wrong technique in device usage process, Device deposit issue, No adverse event, |
||||
ALBUTEROL SULFATE, APIXABAN, |
||||
| 927 | 25063414 |
US |
2 | |
Recalled product administered, No adverse event, |
||||
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, |
||||
| 928 | 25063479 |
US |
||
Recalled product administered, No adverse event, |
||||
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, |
||||
| 929 | 25063748 |
US |
||
Product storage error, No adverse event, |
||||
DORNASE ALFA, |
||||
| 930 | 25063749 |
US |
||
Product storage error, No adverse event, |
||||
DORNASE ALFA, |
||||
| 931 | 25063943 |
US |
63 | 1 |
Off label use, No adverse event, |
||||
VERICIGUAT, |
||||
| 932 | 25063981 |
US |
||
Incorrect dose administered by device, Device delivery system issue, No adverse event, |
||||
TESTOSTERONE, TESTOSTERONE,, |
||||
| 933 | 25063985 |
US |
1 | |
No adverse event, Product dose omission issue, Off label use, |
||||
VEDOLIZUMAB, |
||||
| 934 | 25064047 |
US |
2 | |
Needle issue, No adverse event, |
||||
| 935 | 25064069 |
US |
17 | 1 |
Product prescribing issue, No adverse event, |
||||
EMICIZUMAB, |
||||
| 936 | 25064212 |
US |
||
Wrong technique in product usage process, No adverse event, |
||||
TIOTROPIUM BROMIDE, |
||||
| 937 | 25064227 |
US |
2 | |
Product dose omission issue, Device use error, No adverse event, |
||||
OMALIZUMAB, OMALIZUMAB, MONTELUKAST, |
||||
| 938 | 25064243 |
US |
||
Device malfunction, No adverse event, |
||||
PEGFILGRASTIM-CBQV, |
||||
| 939 | 25064269 |
US |
||
Recalled product administered, No adverse event, |
||||
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, |
||||
| 940 | 25064295 |
US |
||
Recalled product administered, No adverse event, |
||||
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, |
||||
| 941 | 25064329 |
US |
||
Recalled product administered, No adverse event, |
||||
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, |
||||
| 942 | 25064335 |
US |
||
Recalled product administered, No adverse event, |
||||
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, |
||||
| 943 | 25064670 |
US |
1 | 2 |
Product storage error, No adverse event, |
||||
| 944 | 25064673 |
US |
5 | 1 |
Product storage error, No adverse event, |
||||
| 945 | 25064843 |
US |
||
Product storage error, No adverse event, |
||||
| 946 | 25065175 |
US |
||
Insurance issue, Therapy cessation, No adverse event, |
||||
PEMBROLIZUMAB, |
||||
| 947 | 25065285 |
US |
||
No adverse event, Off label use, |
||||
MOSUNETUZUMAB, POLATUZUMAB VEDOTIN, |
||||
| 948 | 25065411 |
US |
||
Underdose, No adverse event, |
||||
| 949 | 25065439 |
US |
1 | |
Product dose omission issue, No adverse event, |
||||
VERICIGUAT, |
||||
| 950 | 25056647 |
US |
2 | |
Off label use, No adverse event, |
||||
OMALIZUMAB, OMALIZUMAB, |
||||
| 951 | 25056765 |
US |
||
Product dose omission issue, Product use issue, No adverse event, |
||||
SITAGLIPTIN, |
||||
| 952 | 25056820 |
US |
||
Wrong technique in product usage process, Device defective, Device malfunction, No adverse event, |
||||
ALBUTEROL SULFATE, ALBUTEROL SULFATE, ALBUTEROL SULFATE, ALBUTEROL SULFATE, |
||||
| 953 | 25056832 |
US |
21 | |
Drug dose omission by device, Wrong technique in product usage process, No adverse event, |
||||
ALBUTEROL SULFATE, ALBUTEROL SULFATE, ALBUTEROL, |
||||
| 954 | 25056972 |
US |
1 | |
Drug ineffective, Product physical consistency issue, Product delivery mechanism issue, No adverse event, |
||||
TRIAMCINOLONE ACETONIDE, |
||||
| 955 | 25057114 |
US |
87 | |
Wrong technique in device usage process, Drug dose omission by device, Device difficult to use, No adverse event, |
||||
TIOTROPIUM BROMIDE, BUDESONIDE, ARFORMOTEROL TARTRATE, ALBUTEROL SULFATE, ALBUTEROL, |
||||
| 956 | 25057129 |
US |
2 | |
No adverse event, Product dose omission issue, |
||||
VEDOLIZUMAB, VEDOLIZUMAB, VEDOLIZUMAB, VEDOLIZUMAB, |
||||
| 957 | 25057174 |
US |
2 | |
No adverse event, Off label use, |
||||
| 958 | 25057279 |
US |
1 | |
No adverse event, Off label use, |
||||
ICATIBANT ACETATE, ICATIBANT ACETATE, |
||||
| 959 | 25057356 |
US |
3 | 2 |
Off label use, No adverse event, |
||||
OMALIZUMAB, |
||||
| 960 | 25057496 |
US |
50 | 2 |
Product dispensing error, No adverse event, |
||||
OMALIZUMAB, |
||||
| 961 | 25057541 |
US |
||
Wrong technique in product usage process, No adverse event, |
||||
ALBUTEROL SULFATE, ALBUTEROL SULFATE, |
||||
| 962 | 25057589 |
US |
||
Recalled product administered, No adverse event, |
||||
RAMIPRIL, |
||||
| 963 | 25057619 |
US |
68 | 1 |
Drug ineffective, No adverse event, |
||||
TOCILIZUMAB, |
||||
| 964 | 25057623 |
US |
2 | |
Product delivery mechanism issue, No adverse event, |
||||
DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, |
||||
| 965 | 25057653 |
|||
Recalled product administered, No adverse event, |
||||
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, |
||||
| 966 | 25057703 |
US |
||
Recalled product administered, No adverse event, |
||||
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, |
||||
| 967 | 25057826 |
US |
||
Recalled product administered, No adverse event, |
||||
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, |
||||
| 968 | 25057925 |
US |
||
Recalled product administered, No adverse event, |
||||
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, |
||||
| 969 | 25057928 |
US |
48 | |
Wrong technique in product usage process, No adverse event, |
||||
ALBUTEROL SULFATE, |
||||
| 970 | 25057941 |
US |
2 | |
No adverse event, |
||||
BELIMUMAB, |
||||
| 971 | 25057992 |
US |
||
Recalled product administered, No adverse event, |
||||
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, |
||||
| 972 | 25058006 |
US |
||
Recalled product administered, No adverse event, |
||||
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, |
||||
| 973 | 25058039 |
US |
||
Recalled product administered, No adverse event, |
||||
RAMIPRIL, RAMIPRIL, RAMIPRIL, RAMIPRIL, |
||||
| 974 | 25058613 |
US |
||
Device malfunction, No adverse event, |
||||
PEGFILGRASTIM-CBQV, |
||||
| 975 | 25058645 |
US |
1 | |
Drug ineffective, No adverse event, |
||||
OMALIZUMAB, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, DUTASTERIDE, MELOXICAM, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, |
||||
| 976 | 25058688 |
US |
1 | |
Drug ineffective, No adverse event, |
||||
OMALIZUMAB, OMALIZUMAB, |
||||
| 977 | 25058717 |
US |
68 | |
Drug dose omission by device, Device delivery system issue, No adverse event, |
||||
LEVALBUTEROL TARTRATE, LEVALBUTEROL TARTRATE, |
||||
| 978 | 25058735 |
US |
2 | |
No adverse event, Product prescribing issue, |
||||
| 979 | 25058772 |
US |
1 | |
Drug ineffective, No adverse event, |
||||
OMALIZUMAB, OMALIZUMAB, |
||||
| 980 | 25058778 |
US |
54 | 2 |
Incorrect dose administered, Product dose omission issue, Product complaint, Device issue, No adverse event, |
||||
OMALIZUMAB, OMALIZUMAB, FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE, FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE, DIPHENHYDRAMINE HYDROCHLORIDE, |
||||
| 981 | 25058779 |
US |
1 | |
Syringe issue, No adverse event, Accidental exposure to product, |
||||
OMALIZUMAB, OMALIZUMAB, |
||||
| 982 | 25058934 |
US |
2 | |
Product use in unapproved indication, No adverse event, |
||||
PEMBROLIZUMAB, |
||||
| 983 | 25058999 |
US |
70 | 2 |
Product dose omission issue, No adverse event, |
||||
FAM-TRASTUZUMAB DERUXTECAN-NXKI, |
||||
| 984 | 25059061 |
US |
36 | 2 |
Off label use, Product dose omission issue, Maternal exposure before pregnancy, No adverse event, Device defective, Maternal exposure during pregnancy, |
||||
OMALIZUMAB, OMALIZUMAB, FLUTICASONE FUROATE AND VILANTEROL TRIFENATATE, MONTELUKAST SODIUM, |
||||
| 985 | 25059080 |
US |
46 | 2 |
Off label use, No adverse event, |
||||
OMALIZUMAB, |
||||
| 986 | 25059100 |
US |
37 | 1 |
Overdose, No adverse event, |
||||
OMALIZUMAB, OMALIZUMAB, |
||||
| 987 | 25059101 |
US |
2 | |
Syringe issue, Product dose omission issue, No adverse event, |
||||
OMALIZUMAB, OMALIZUMAB, |
||||
| 988 | 25059117 |
JP |
||
No adverse event, |
||||
DARBEPOETIN ALFA, |
||||
| 989 | 25059167 |
US |
||
No adverse event, |
||||
RISPERIDONE, RISPERIDONE, RISPERIDONE, RISPERIDONE, RISPERIDONE, RISPERIDONE, |
||||
| 990 | 25059481 |
US |
23 | 2 |
Complication of device removal, Device issue, Device deployment issue, No adverse event, |
||||
ETONOGESTREL, |
||||
| 991 | 25059540 |
US |
||
Off label use, No adverse event, |
||||
RISDIPLAM, ONASEMNOGENE ABEPARVOVEC-XIOI, |
||||
| 992 | 25059581 |
US |
2 | |
Product dose omission issue, Exposure via skin contact, Syringe issue, No adverse event, |
||||
SOTATERCEPT-CSRK, SOTATERCEPT-CSRK, SOTATERCEPT-CSRK, SOTATERCEPT-CSRK, |
||||
| 993 | 25059613 |
US |
2 | |
Extra dose administered, No adverse event, |
||||
FEXOFENADINE HYDROCHLORIDE, |
||||
| 994 | 25059632 |
US |
1 | |
Drug ineffective, No adverse event, |
||||
AMLODIPINE BESYLATE, COLESTIPOL HYDROCHLORIDE, EPINEPHRINE, FLUTICASONE PROPIONATE, TRIPROLIDINE HCL, ACETAMINOPHEN, CHLORPHENIRAMINE MALEATE, PHENYLEPHRINE HCL, LISINOPRIL, MONTELUKAST SODIUM, PANTOPRAZOLE SODIUM, ROSUVASTATIN, SERTRALINE HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE, OMALIZUMAB, VALACYCLOVIR HYDROCHLORIDE, HYDROXYZINE, |
||||
| 995 | 25059635 |
US |
2 | |
Drug ineffective, No adverse event, |
||||
| 996 | 25059927 |
US |
||
Product storage error, No adverse event, |
||||
| 997 | 25060351 |
US |
66 | 2 |
No adverse event, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 998 | 25060446 |
US |
54 | |
Drug dose omission by device, Wrong technique in product usage process, No adverse event, |
||||
ALBUTEROL SULFATE, BUDESONIDE, GLYCOPYRROLATE, AND FORMOTEROL FUMARATE, |
||||
| 999 | 25060556 |
US |
26 | 2 |
Wrong technique in device usage process, Exposure via skin contact, Product dose omission issue, Device issue, Device difficult to use, No adverse event, |
||||
OMALIZUMAB, OMALIZUMAB, PREDNISONE, |
||||
| 1000 | 25060864 |
US |
2 | |
No adverse event, Product dose omission issue, |
||||
VEDOLIZUMAB, VEDOLIZUMAB, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2025-04-28